WO2004060385A1 - 眼科用治療組成物 - Google Patents
眼科用治療組成物 Download PDFInfo
- Publication number
- WO2004060385A1 WO2004060385A1 PCT/JP2003/016514 JP0316514W WO2004060385A1 WO 2004060385 A1 WO2004060385 A1 WO 2004060385A1 JP 0316514 W JP0316514 W JP 0316514W WO 2004060385 A1 WO2004060385 A1 WO 2004060385A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- corneal
- peptide
- ophthalmic
- phsrn
- pharmaceutically acceptable
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 37
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 208000028006 Corneal injury Diseases 0.000 claims abstract description 8
- 239000002552 dosage form Substances 0.000 claims abstract description 7
- 208000021921 corneal disease Diseases 0.000 claims description 23
- 239000003889 eye drop Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 210000003560 epithelium corneal Anatomy 0.000 claims description 9
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 8
- 206010013774 Dry eye Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 201000007717 corneal ulcer Diseases 0.000 claims description 7
- 206010023332 keratitis Diseases 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 6
- 206010064996 Ulcerative keratitis Diseases 0.000 claims description 5
- 230000000069 prophylactic effect Effects 0.000 claims description 5
- 230000003449 preventive effect Effects 0.000 claims 3
- 108010067306 Fibronectins Proteins 0.000 abstract description 24
- 102000016359 Fibronectins Human genes 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 19
- 239000002997 ophthalmic solution Substances 0.000 abstract description 8
- 229940054534 ophthalmic solution Drugs 0.000 abstract description 6
- 108010039042 prolyl-histidyl-seryl-arginyl-asparagine Proteins 0.000 abstract description 3
- 210000004087 cornea Anatomy 0.000 description 20
- 230000029663 wound healing Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 229940012356 eye drops Drugs 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 206010052428 Wound Diseases 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 101800003838 Epidermal growth factor Proteins 0.000 description 6
- 102400001368 Epidermal growth factor Human genes 0.000 description 6
- 229940116977 epidermal growth factor Drugs 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 239000003885 eye ointment Substances 0.000 description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- -1 paratoluene Sulfonates Chemical class 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- 241000272875 Ardeidae Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- MFRCZYUUKMFJQJ-UHFFFAOYSA-N 1,4-dioxane-2,5-dione;1,3-dioxan-2-one Chemical compound O=C1OCCCO1.O=C1COC(=O)CO1 MFRCZYUUKMFJQJ-UHFFFAOYSA-N 0.000 description 1
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- 206010011026 Corneal lesion Diseases 0.000 description 1
- 206010066786 Diabetic keratopathy Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004045 bowman membrane Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000002555 descemet membrane Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 108010025899 gelatin film Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229940125702 ophthalmic agent Drugs 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 108010091748 peptide A Proteins 0.000 description 1
- 108010091867 peptide P Proteins 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to ophthalmic therapeutic compositions.
- the present invention relates to proline-histidine-serine-arginine-asparagine, which is the active site of fibronectin, and a chemical substance (hereinafter referred to as PHSRN or Ac-Pro-His-Ser -Arg_Asn - and NH 2) it is also of the related.
- the present invention also relates to an ophthalmic therapeutic composition and / or a prophylactic composition containing a pharmaceutically acceptable salt of this substance as an active ingredient.
- This composition relates to an agent for preventing or treating corneal disorders, which has an effect of promoting wound healing of corneal epithelium.
- the cornea is a thin tissue with a thickness of 0.52 mm to 1.0 mm.
- the cornea located at the forefront of the eyeball, is a highly differentiated tissue that has permeability and appropriate refractive power to direct light from the outside world to receptors in the retina.
- the cornea also has extremely important physiological functions.
- the structure of the cornea is relatively simple. That is, the cornea has a very regular and fine quintuple structure composed of an epithelial layer, Bowman's membrane, corneal stromal layer, Descemet's membrane and endothelial cell layer.
- Fibronectin is a glycoprotein with a molecular weight of about 440000 that is involved in cell adhesion and spreading, and plays an important role in biological phenomena such as morphogenesis and development in addition to wound healing. This fibronectin is a dimer in which two subunits with a molecular weight of 220,000 to 250,000 are linked. Fibronectin has a domain structure. Fibronectin specifically binds to various extracellular matrices and cross-links with the fibronectin receptor (integrin) on the cell surface to adhere to cells. Are involved in
- Corneal disorders can be caused by various diseases such as corneal ulcers, corneal epithelial sculpture, keratitis or dry eye. This disorder can be repaired spontaneously in the absence of concurrent infection.
- the principle of repair is as follows: (1) When the cornea is damaged, fibronectin appears in the exposed corneal stromal area where the epithelium is defective, (2) this fibronectin adheres to the matrix, and (3) epithelial cells extend and migrate to this matrix. That is. As the cornea heals, fibronectin disappears from the corneal lesion.
- the repair may be delayed for any reason, or the epithelial defect may be prolonged without repair. Then, in addition to adversely affecting the normal construction of the epithelium, the structure and function of the substance and endothelium are also impaired. Conventional treatment is passive, in which the epithelium expands spontaneously to re-cover the defect by protecting the corneal surface from external stimuli. In recent years, with the development of cell biology, factors involved in cell division, migration, adhesion and spreading have been elucidated. In repairing corneal epithelial defects, compounds that promote corneal epithelial extension have been regarded as important.
- Known therapeutic agents for corneal epithelial wounds include components such as fibronectin, EGF (Epidermal Growth Factor), and hyaluronic acid.
- Fibronectin present in human plasma can be purified and used as an ophthalmic blood product. It is known that this ophthalmic solution promotes recoating of corneal epithelial defects and promotes epithelial wound healing.
- fibronectin must be purified using a patient's own plasma and a special purification kit. For this reason, obtaining fibronectin is very time-consuming and burdens patients. For this reason, fibronectin is clinically effective but has not been fully utilized.
- EGF Epidermal Growth Factor
- corneal epithelial mitotic growth factor is known. It is known that EGF effects are difficult to exert when factors that inhibit epithelial division are present. In addition, in cases involving inflammation and diabetic keratopathy, there is a problem that angiogenesis occurs as a side effect of EGF.
- Hyal humic acid is a darcosaminodalican with a molecular weight of several millions, which comprises N-acetyl-D-darcosamine and D-darc hydric acid as constituent sugars. It is known that hyaluronic acid has a remarkable therapeutic effect as a therapeutic agent for dry eye. The action of hyaluronic acid mainly acts on the adhesion and development of epithelial cells, and the effect on proliferation of epithelial cells is weak. Hyaluronic acid has the drawback that it is difficult to use as an eye drop because its viscosity increases at high concentrations.
- the peptide PHSRN is disclosed in International Publication No. WO 98/22671 and the Journal of Clinical Investigation, 105 (11), pl537-1545, 2000,
- the PHSRN sequence induces extracellular matrix invasion and It is a pentapeptide disclosed in accelerates wound healing in obese diabetic mice.
- These prior art documents describe that the peptide PHSRN has a wound healing and cancer cell invasion / proliferation inhibitory effect.
- no report on the ophthalmic field for the peptide PHSRN is known.
- fibronectin has been recognized as clinically effective in the ophthalmic field.
- fibronectin has problems specific to blood products (for example, hygiene problems, the burden of collecting blood by patients themselves, and the complexity of purifying fibronectin from plasma). Therefore, it has not been widely used.
- the active site of fibronectin has not been sufficiently clarified, there is still room for further research and development for using fibronectin as an active ingredient of a therapeutic agent for corneal disorders.
- the present invention has been made under the above circumstances.
- One object is to find a fibronectin active expression site, and another object is to use a fibronectin active expression site for an ophthalmic treatment. It is to provide a composition that can be used as a drug or Z and a prophylactic agent. Disclosure of the invention
- the present inventors focused on peptides contained in fibronectin, and examined the effects on corneal disorders. As a result, the present inventors have found that PH SRN, which is a site where fibronectin activity is expressed, promotes wound healing of corneal epithelium.
- the present inventors have found a new use of PHSRN as an ophthalmic treatment composition, and 2 a corneal disorder such as corneal ulcer, corneal epithelial detachment, keratitis or dry eye in which the cornea is damaged.
- a composition using PHSRN or a pharmaceutically acceptable salt thereof is useful as a prophylactic or / and therapeutic agent for the present invention, and basically completed the present invention.
- the present invention provides a novel composition for ophthalmic treatment which exhibits a strong therapeutic effect on corneal disorders in a small amount, and is low in molecular weight and excellent in safety.
- the present invention provides the following.
- An ophthalmic therapeutic composition containing the peptide PHSRN or a pharmaceutically acceptable salt of the peptide as an active ingredient.
- corneal disorder is corneal ulcer, corneal epithelial detachment, keratitis or dry eye.
- Peptide PHS RN or a pharmaceutically acceptable drug for this peptide A corneal epithelial extension promoter comprising a salt as an active ingredient.
- amino acid residues Asparagine means Asn or N
- arginine means Arg or R
- histidine means His or H
- proline means Pro or P
- serine means Ser or S.
- Ac represents an acetyl group
- NH 2 represents an amino group.
- the peptide PHSRN has a structure of pentapeptide, Pro-His-Ser-Arg-Asn, which is the active site of fibronectin. Where the amino acids can form multiple enantiomers, all of these enantiomers and mixtures thereof are all included in the present invention. Compositions formed with the peptide PHS RN as a motif should be construed as equivalent scope within the scope of the present invention. Further, in the peptide PHS RN, a substance in which the N-terminal is acetylated and the C-terminal is amidated, that is, Ac—Pro—His—Ser—Arg—Asn—NH 2 is preferred.
- prevention refers to preventing the occurrence of a disease (prevention) or curing a patient suffering from the disease (treatment) by administering to an animal including a human. Means.
- the corneal disorder referred to in the present invention refers to corneal ulcer, corneal epithelial detachment, keratitis, dry eye and the like in which the cornea is damaged by various factors.
- Pharmaceutically acceptable salts of the peptide PHS RN include, for example, hydrochloride, sulfate, phosphate, lactate, maleate, fumarate, oxalate, methanesulfonate, paratoluene Sulfonates and the like.
- the peptide PH SRN or a pharmaceutically acceptable salt of the peptide, can be administered orally or parenterally.
- Dosage forms include tablets, capsules, granules, powders, injections, eye drops and the like. Of these, Ophthalmic solutions such as eye drops and eye ointments are preferred. These can be formulated using commonly used techniques.
- excipients such as lactose, crystalline cellulose, starch, vegetable oil, magnesium stearate, talc, etc.1J, hydroxypropylcellulose , Polyvinyl pyrrolidone, etc.
- binders such as carboxymethylcellulose calcium, low-substituted hydroxypropylmethylcellulose, etc., coating agents such as hydroxypropylmethylcellulose, macrogol, silicon resin, etc., films such as gelatin film Agents and the like may be added as needed.
- eye drops it can be formulated using an isotonic agent such as sodium chloride, a buffering agent such as sodium phosphate, a preservative such as benzalco-pam chloride, and the like.
- the pH of these drugs may be within the range acceptable for ophthalmic preparations, but is preferably in the range of 4 to 8.
- an eye ointment it can be prepared using a commonly used base such as white glycerin or liquid paraffin.
- the therapeutic agent for corneal disorders of the present invention is preferably administered topically, particularly as an eye drop.
- concentration of the peptide PHSRN in the ophthalmic solution may be set according to symptoms, age, etc., and is not particularly limited, but is preferably 0.0001% to 1%.
- eye drops one to several drops can be administered at a time, and once to several times a day.
- eye drops in addition to ordinary eye drops, dissolvable eye drops and eye ointments may be used.
- tonicity agents such as sodium chloride and potassium chloride
- buffers such as sodium hydrogen phosphate and sodium dihydrogen phosphate
- stabilizers such as sodium edetate, etylparaben, butylparaben
- Preservatives such as benzalkonium chloride
- pH adjusters such as sodium hydroxide and dilute hydrochloric acid
- additives such as white ophthalmic saline, liquid paraffin and other ointment bases as needed, and formulated in the usual manner.
- the peptide PHSRN according to the present invention can be prepared by a method used in ordinary peptide synthesis, such as a solid phase method in which a peptide chain is extended from the C-terminal on an insoluble polymer carrier, or a liquid phase method using no carrier. It can be manufactured easily and inexpensively.
- the use of the peptide PHSRN of the present invention for industrially producing the ophthalmic agent of the present invention, and a therapeutic method of administering to the patient using the same are also included in the scope of the present invention.
- FIG. 1 is a graph showing the effect of the peptide PHS RN on the extension of corneal epithelial cells.
- the horizontal axis represents the concentration of peptide PH SRN (0 (control), 51.2 ⁇ , 102.5 ⁇ , 153.7 ⁇ , 256.2 ⁇ , 51.2 ⁇ )
- the vertical axis indicates the extension length (/ m) of the corneal epithelium.
- the present inventors examined the effect of the peptide PHSRN on corneal disorders in order to examine the usefulness of the peptide PHSRN. The details are shown in the section on pharmacological tests below. The present inventors have found that eye drops of the peptide PHSRN have the following effects: (1) a corneal epithelium extending effect in a tissue culture system of corneal slices; and (2) an effect of promoting wound healing after corneal epithelial detachment.
- peptide PHS RN can be associated with corneal disorders (ie, corneal ulcers, corneal epithelial detachments, keratitis, dry eye, etc., especially corneal epithelial detachments, in which the cornea is damaged by various factors) and dry corneal epithelium. It was found to be useful for treating eye.
- Cornea blocks (3 per group) were cut out from heron corneal slices.
- the corneal block was cultured in a culture solution containing the test compound (Medium-199) at 37 ° C. and 5% CO 2 for 20 hours. After culturing, the corneal block was fixed in a mixed solution of ethanol and ice (95: 5 by volume) and embedded in paraffin to prepare sections. The sections were deparaffinized, stained with hematoxylin-eosin, and the extension length of the epithelial cell layer was measured with a microscope. Controls that had been similarly cultured in a culture solution containing no test compound were used.
- corneal epithelial detachment was caused according to the method of Cintron et al. (Ophthalmic Res., 11, 90-96 (1979)), and a wound with a diameter of about 6 cm was created in the cornea.
- the wound area was measured using the area of fluorescein staining as an index. The effect of the test compound on corneal wound healing was examined.
- ophthalmic solution containing the test compound at each concentration was applied to the eye (SO LZ Times).
- fluorescein staining was performed and a photograph of the cornea was measured.
- the area of fluorescein staining of the photographed cornea was calculated using an image analysis processing system.
- a heron instilled with a base (PBS) containing no test compound was used as a control.
- FIG. 3 shows the post-healing effect on Ac-Pro-His-Ser-Arg-Asn-N3 ⁇ 4 (PHS RN) by the cure rate. As shown in Tables 1 and 2, it was recognized that the instillation of the peptide PH SRN showed a remarkable promotion on wound healing.
- each value represents the mean ⁇ standard deviation (n-6).
- Statistical analysis was performed using Durmett's multiple comparison with PBS, and the area of the corneal injury site immediately after corneal epithelial detachment (0 hour) was set to 100% (* p ⁇ 0.05, ** ⁇ 0.01; vs control).
- corneal epithelial detachment was caused using Japanese white egrets, and wounds with a diameter of about 8 were created in the cornea. Wound area is indicated by fluorescein staining area The effect on corneal wound healing was examined.
- eye drops containing the test compound at each concentration were instilled (25 times) at 0, 6, 12, 18, 24, 30, 36, 42, 48 and 54 hours.
- fluorescein staining was performed and a photograph of the cornea was measured.
- the area of fluorescein staining of the photographed cornea was calculated using an image analysis processing system.
- a heron instilled with a base (saline) containing no test compound was used as a control.
- Statistical analysis was performed using Dunnett's multiple comparison with saline, and the area of the corneal injury site immediately after corneal epithelial detachment (0 hour) was set to 100% (* p ⁇ 0.05, ** p ⁇ 0.01; vs control) .
- HSRN has a corneal epithelial wound healing promoting effect and prevents corneal disorders such as corneal ulcer, corneal epithelial detachment, keratitis or dry eye in which the cornea is damaged by various factors Was found to be useful as an agent or / and a therapeutic agent.
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES03786242.2T ES2475243T3 (es) | 2002-12-27 | 2003-12-24 | Uso del pentap�ptido PHSRN en formulaciones oft�lmicas |
AU2003296060A AU2003296060A1 (en) | 2002-12-27 | 2003-12-24 | Ophthalmic therapeutic composition |
EP03786242.2A EP1586324B1 (en) | 2002-12-27 | 2003-12-24 | Use of the pentapeptide PHSRN in ophthalmic formulations |
US10/540,446 US20060234945A1 (en) | 2002-12-27 | 2003-12-24 | Ophthalmic therapeutic composition |
US12/559,704 US8207119B2 (en) | 2002-12-27 | 2009-09-15 | Ophthalmological composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-381131 | 2002-12-27 | ||
JP2002381131A JP4313033B2 (ja) | 2002-12-27 | 2002-12-27 | 眼科用治療組成物 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/540,446 A-371-Of-International US20060234945A1 (en) | 2002-12-27 | 2003-12-24 | Ophthalmic therapeutic composition |
US12/559,704 Division US8207119B2 (en) | 2002-12-27 | 2009-09-15 | Ophthalmological composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004060385A1 true WO2004060385A1 (ja) | 2004-07-22 |
Family
ID=32708470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/016514 WO2004060385A1 (ja) | 2002-12-27 | 2003-12-24 | 眼科用治療組成物 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20060234945A1 (ja) |
EP (1) | EP1586324B1 (ja) |
JP (1) | JP4313033B2 (ja) |
AU (1) | AU2003296060A1 (ja) |
ES (1) | ES2475243T3 (ja) |
WO (1) | WO2004060385A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009102285A (ja) * | 2007-10-25 | 2009-05-14 | Nippon Tenganyaku Kenkyusho:Kk | 細胞間接着増強剤 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997049419A1 (fr) * | 1996-06-26 | 1997-12-31 | Santen Pharmaceutical Co., Ltd. | Compositions medicamenteuses ophtalmiques |
US6025150A (en) * | 1996-11-21 | 2000-02-15 | The Regents Of The University Of Michigan | Methods and compositions for wound healing |
WO2000041729A1 (fr) * | 1999-01-12 | 2000-07-20 | Santen Pharmaceutical Co., Ltd. | Medicaments contre les troubles de la cornee |
WO2001091795A1 (fr) * | 2000-05-30 | 2001-12-06 | Santen Pharmaceutical Co., Ltd. | Promoteurs de l'extension de l'epithelium corneen |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4713446A (en) * | 1985-09-06 | 1987-12-15 | Minnesota Mining And Manufacturing Company | Viscoelastic collagen solution for ophthalmic use and method of preparation |
FI854634A0 (fi) * | 1985-11-22 | 1985-11-22 | Labsystems Oy | Foerfarande foer bestaemning av proteolytisk aktivitet. |
JPH03291238A (ja) * | 1989-12-27 | 1991-12-20 | Takara Shuzo Co Ltd | 角膜障害治療剤 |
SE470477B (sv) * | 1992-10-05 | 1994-05-24 | Procell Bioteknik Ab | Salva innehållande fibronektin för behandling av sår |
US6331409B1 (en) * | 1996-11-21 | 2001-12-18 | The Regents Of The University Of Michigan | Methods and compositions for wound healing |
EP0928340B1 (en) * | 1996-11-21 | 2009-06-10 | The Regents Of The University Of Michigan | Invasion-inhibitors for use in wound healing and cancer |
US5840514A (en) * | 1996-11-21 | 1998-11-24 | The Regents Of The University Of Michigan | Methods of testing cancer and anticancer drugs |
US6194378B1 (en) * | 1998-02-18 | 2001-02-27 | The Research Foundation Of State University Of New York | Fibronectin peptides-based extracellular matrix for wound healing |
US6104068A (en) * | 1998-09-01 | 2000-08-15 | Micron Technology, Inc. | Structure and method for improved signal processing |
JP2000264847A (ja) | 1999-01-12 | 2000-09-26 | Teruo Nishida | 角膜障害治療剤 |
JP4003008B2 (ja) | 2000-05-30 | 2007-11-07 | 参天製薬株式会社 | 角膜上皮伸展促進剤 |
US6743149B2 (en) * | 2000-07-17 | 2004-06-01 | Nissan Motor Co., Ltd. | Toroidal continuously variable transmission |
-
2002
- 2002-12-27 JP JP2002381131A patent/JP4313033B2/ja not_active Expired - Fee Related
-
2003
- 2003-12-24 WO PCT/JP2003/016514 patent/WO2004060385A1/ja active Application Filing
- 2003-12-24 EP EP03786242.2A patent/EP1586324B1/en not_active Expired - Lifetime
- 2003-12-24 US US10/540,446 patent/US20060234945A1/en not_active Abandoned
- 2003-12-24 ES ES03786242.2T patent/ES2475243T3/es not_active Expired - Lifetime
- 2003-12-24 AU AU2003296060A patent/AU2003296060A1/en not_active Abandoned
-
2009
- 2009-09-15 US US12/559,704 patent/US8207119B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997049419A1 (fr) * | 1996-06-26 | 1997-12-31 | Santen Pharmaceutical Co., Ltd. | Compositions medicamenteuses ophtalmiques |
US6025150A (en) * | 1996-11-21 | 2000-02-15 | The Regents Of The University Of Michigan | Methods and compositions for wound healing |
WO2000041729A1 (fr) * | 1999-01-12 | 2000-07-20 | Santen Pharmaceutical Co., Ltd. | Medicaments contre les troubles de la cornee |
WO2001091795A1 (fr) * | 2000-05-30 | 2001-12-06 | Santen Pharmaceutical Co., Ltd. | Promoteurs de l'extension de l'epithelium corneen |
Non-Patent Citations (6)
Title |
---|
AUCOIN L. ET AL: "Interactions of corneal epithelial cells and surfaces modified with cell adhesion peptide combinations", J. OF BIOMATERIALS SCIENCE, vol. 13, no. 4, 2002, pages 447 - 462, XP002978005 * |
AUCOIN L., JOURNAL OF BIOMATERIALS SCIENCE, vol. 13, no. 4, 2002 |
LIVAN D.L. ET AL., JOURNAL OF CLINICAL INVETIGATION, vol. 105, no. 11, June 2000 (2000-06-01) |
LIVAN D.L. ET AL: "The PHSRN sequence induces extracellular matrix invasion and accelerates wound healin in obese diabetic mice", J. OF CLINICAL INVESTIGATION, vol. 105, no. 11, June 2000 (2000-06-01), pages 1537 - 1545, XP001147066 * |
See also references of EP1586324A4 |
THE JOURNAL OF CLINICAL INVESTIGATION, vol. 105, no. 11, 2000, pages 1537 - 1545 |
Also Published As
Publication number | Publication date |
---|---|
US20100099629A1 (en) | 2010-04-22 |
EP1586324A4 (en) | 2007-06-06 |
JP4313033B2 (ja) | 2009-08-12 |
ES2475243T3 (es) | 2014-07-10 |
JP2004210692A (ja) | 2004-07-29 |
US8207119B2 (en) | 2012-06-26 |
EP1586324A1 (en) | 2005-10-19 |
EP1586324B1 (en) | 2014-04-16 |
US20060234945A1 (en) | 2006-10-19 |
AU2003296060A1 (en) | 2004-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8183343B2 (en) | Methods for treating a skin wound | |
KR20210061372A (ko) | 몬테루카스트와 펩티드의 새로운 접합체 | |
AU2001277767B2 (en) | Skin wound healing promoters | |
JP3191038B2 (ja) | 眼科用医薬組成物 | |
JP4249025B2 (ja) | ドライアイおよびドライアイを伴う疾病の治療剤 | |
MXPA06012175A (es) | Promotor de neuritogenesis corneal que contiene polipeptido activador de la adenilato ciclasa de la pituitaria y sus derivados. | |
JP5898672B2 (ja) | セマフォリン阻害剤を有効成分とする角膜知覚神経障害治療薬 | |
US20080300182A1 (en) | Eye disease treating agent and method for treating eye disease | |
JP4253743B2 (ja) | 新規ペプチドおよびその医薬用途 | |
WO2004060385A1 (ja) | 眼科用治療組成物 | |
JP2534176B2 (ja) | 角膜上皮欠損等の治療剤 | |
JP7328696B2 (ja) | 角膜上皮細胞走化促進剤 | |
JP5546756B2 (ja) | 角膜保護剤および角膜障害改善剤 | |
JP2000264847A (ja) | 角膜障害治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003786242 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003786242 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006234945 Country of ref document: US Ref document number: 10540446 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10540446 Country of ref document: US |